147 related articles for article (PubMed ID: 2491983)
1. Removal of viral contaminants by monoclonal antibody purification of plasma proteins.
Schreiber AB; Hrinda ME; Newman J; Tarr GC; D'Alisa R; Curry WM
Curr Stud Hematol Blood Transfus; 1989; (56):146-53. PubMed ID: 2491983
[TBL] [Abstract][Full Text] [Related]
2. Affinity chromatography to remove viruses during preparation of plasma derivatives.
Lawrence JE
Dev Biol Stand; 1993; 81():191-7. PubMed ID: 8174803
[TBL] [Abstract][Full Text] [Related]
3. Pasteurized, monoclonal antibody factor VIII concentrate: establishing a new standard for purity and viral safety of plasma-derived concentrates.
Goldsmith JC
Blood Coagul Fibrinolysis; 2000 Mar; 11(2):203-15. PubMed ID: 10759015
[TBL] [Abstract][Full Text] [Related]
4. Immunoaffinity purification of factor VIII.
Weinstein RE
Ann Clin Lab Sci; 1989; 19(2):84-91. PubMed ID: 2502062
[TBL] [Abstract][Full Text] [Related]
5. Treatment of hemophilia A with a highly purified factor VIII concentrate prepared by anti-FVIIIc immunoaffinity chromatography.
Addiego JE; Gomperts E; Liu SL; Bailey P; Courter SG; Lee ML; Neslund GG; Kingdon HS; Griffith MJ
Thromb Haemost; 1992 Jan; 67(1):19-27. PubMed ID: 1615478
[TBL] [Abstract][Full Text] [Related]
6. Large-scale production and properties of human plasma-derived activated Factor VII concentrate.
Tomokiyo K; Yano H; Imamura M; Nakano Y; Nakagaki T; Ogata Y; Terano T; Miyamoto S; Funatsu A
Vox Sang; 2003 Jan; 84(1):54-64. PubMed ID: 12542734
[TBL] [Abstract][Full Text] [Related]
7. [Evaluation of viral safety of a high-purity human factor VIII concentrate submitted to 2 specific virus inactivation treatments (FANDHI)].
Ristol P; Gensana M; Fernández J; Massot M; Biescas H; Darling A; Jorquera JI; Vericat F
Sangre (Barc); 1996 Apr; 41(2):131-6. PubMed ID: 9045353
[TBL] [Abstract][Full Text] [Related]
8. Initial clinical experience with a new pasteurized monoclonal antibody purified factor VIIIC.
Smith KJ; Lusher JM; Cohen AR; Salzman P
Semin Hematol; 1990 Apr; 27(2 Suppl 2):25-9. PubMed ID: 2128855
[TBL] [Abstract][Full Text] [Related]
9. Improved safety from plasma derivatives: purification and viral elimination characteristics of mononine.
Feldman F; Chandra S; Huang C
Acta Haematol; 1995; 94 Suppl 1():25-32; discussion 33-4. PubMed ID: 7571992
[TBL] [Abstract][Full Text] [Related]
10. Ultracentrifugal analysis of factor VIII and von Willebrand factor in therapeutic preparations.
Aronson DL; Chang P
Vox Sang; 1995; 69(1):8-13. PubMed ID: 7483501
[TBL] [Abstract][Full Text] [Related]
11. Preclinical characterization of a new pasteurized monoclonal antibody purified factor VIIIC.
Hrinda ME; Feldman F; Schreiber AB
Semin Hematol; 1990 Apr; 27(2 Suppl 2):19-24. PubMed ID: 2128854
[TBL] [Abstract][Full Text] [Related]
12. Inactivation of HIV-1 and HIV-2 by various manufacturing procedures for human plasma proteins.
Hilfenhaus JW; Gregersen JP; Mehdi S; Volk R
Cancer Detect Prev; 1990; 14(3):369-75. PubMed ID: 2117485
[TBL] [Abstract][Full Text] [Related]
13. Immunoaffinity purification of factor VIII complex.
Hornsey VS; Griffin BD; Pepper DS; Micklem LR; Prowse CV
Thromb Haemost; 1987 Feb; 57(1):102-5. PubMed ID: 3109055
[TBL] [Abstract][Full Text] [Related]
14. Manufacturing process of anti-thrombin III concentrate: viral safety validation studies and effect of column re-use on viral clearance.
Morrica A; Nardini C; Falbo A; Bailey AC; Bucci E
Biologicals; 2003 Sep; 31(3):165-73. PubMed ID: 12935804
[TBL] [Abstract][Full Text] [Related]
15. Viral safety and inhibitor development associated with factor VIIIC ultra-purified from plasma in hemophiliacs previously unexposed to factor VIIIC concentrates. The Monoclate Study Group.
Lusher JM; Salzman PM
Semin Hematol; 1990 Apr; 27(2 Suppl 2):1-7. PubMed ID: 1965615
[TBL] [Abstract][Full Text] [Related]
16. Removal and inactivation of hepatitis B virus from contaminated pooled plasma in a large-scale manufacturing process for factor VIII and human serum albumin.
Murozuka T; Aoki M; Kimura N; Sotoyama K; Abe I; Izumi H; Emura H; Takeda Y; Nanakawa H; Katsubayashi Y; Takeuchi T; Ito H; Hirakawa S; Mitsunaga S; Tadokoro K; Kanemitsu K; Miyamoto M; Yamanaka R; Nishioka K
Vox Sang; 1999; 76(3):181-6. PubMed ID: 10341335
[TBL] [Abstract][Full Text] [Related]
17. Chromatographic removal of viruses from plasma derivatives.
Burnouf T
Dev Biol Stand; 1993; 81():199-209. PubMed ID: 8174804
[TBL] [Abstract][Full Text] [Related]
18. Human anti-mouse immunoglobulins in sera of patients treated chronically with monoclonal antibody-purified factor VIII.
Haimovich J; Davis HM; Schreiber AB
Semin Hematol; 1990 Apr; 27(2 Suppl 2):11-5. PubMed ID: 2128852
[TBL] [Abstract][Full Text] [Related]
19. Specific inactivation of viruses which can potentially contaminate blood products.
Horowitz B
Dev Biol Stand; 1991; 75():43-52. PubMed ID: 1794631
[TBL] [Abstract][Full Text] [Related]
20. Removal of parvovirus B19 from contaminated factor VIII during fractionation.
Schwarz TF; Roggendorf M; Hottenträger B; Stolz W; Schwinn H
J Med Virol; 1991 Sep; 35(1):28-31. PubMed ID: 1940880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
